Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia

Phase 4 Completed 96 enrolled Seoul National University Bundang Hospital

RandomizedParallel-groupSingle-blindTreatment

Summary

In anesthesia for ablation for cardiac arrhythmias, abrupt hemodynamic changes or fatal arrhythmias can be seen frequently. Remimazolam is a novel ultra-short acting benzodiazepine that provides good hemodynamic stability compared to conventional anesthetic agents. This study aims to investigate whether remimazolam reduces vasoactive agent use during cryo/radiofrequancy ablation under general anesthesia, compared to desflurane(RCT).

Timeline

Start: 2022-08-02
Primary completion: 2023-05-19
Completion: 2023-05-19

Outcome

Met primary endpoint

paper The remimazolam group showed a significantly lower incidence of hypotensive events (14/47, 30%) than the desflurane group (29/49, 59%; relative risk [RR], 0.5; PMID 38609684 ↗

paper 95% confidence interval [CI], 0.31 to 0.83; P = 0.004). PMID 38609684 ↗

Publications

Yim S, Choi CI, Park I, Koo BW, Oh AY, Song IA. Remimazolam to prevent hemodynamic instability during catheter ablation under general anesthesia: a randomized controlled trial. Can J Anaesth. 2024 Aug;71(8):1067-1077. doi: 10.1007/s12630-024-02735-z. Epub 2024 Apr 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Remimazolam	Small molecule	—	Intravenous